Your browser doesn't support javascript.
loading
Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses
Jennifer Hicks; Carleen Klumpp-Thomas; Heather Kalish; Anandakumar Shunmugavel; Jennifer Mehalko; John-Paul Denson; Kelly Snead; Matthew Drew; Kizzmekia Corbett; Barney Graham; Matthew D Hall; Dominic Esposito; Kaitlyn Sadtler.
Afiliación
  • Jennifer Hicks; National Institutes of Health
  • Carleen Klumpp-Thomas; National Institutes of Health
  • Heather Kalish; National Institutes of Health
  • Anandakumar Shunmugavel; National Institutes of Health
  • Jennifer Mehalko; Frederick National Laboratory for Cancer Research
  • John-Paul Denson; Frederick National Laboratory for Cancer Research
  • Kelly Snead; Frederick National Laboratory for Cancer Research
  • Matthew Drew; Frederick National Laboratory for Cancer Research
  • Kizzmekia Corbett; National Institutes of Health
  • Barney Graham; National Institutes of Health
  • Matthew D Hall; National Institutes of Health
  • Dominic Esposito; Frederick National Laboratory for Cancer Research
  • Kaitlyn Sadtler; National Institutes of Health
Preprint en Inglés | medRxiv | ID: ppmedrxiv-20137695
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
In order to properly understand the spread of SARS-CoV-2 infection and development of humoral immunity, researchers have evaluated the presence of serum antibodies of people worldwide experiencing the pandemic. These studies rely on the use of recombinant proteins from the viral genome in order to identify serum antibodies that recognize SARS-CoV-2 epitopes. Here, we discuss the cross-reactivity potential of SARS-CoV-2 antibodies with the full spike proteins of four other Betacoronaviruses that cause disease in humans, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-HKU1. Using enzyme-linked immunosorbent assays (ELISAs), we detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies, as expected based on sequence homology of their respective spike proteins. Further analysis of cross-reactivity could provide informative data that could lead to intelligently designed pan-coronavirus therapeutics or vaccines.
Licencia
cc0
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Experimental_studies / Rct Idioma: Inglés Año: 2020 Tipo del documento: Preprint
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Experimental_studies / Rct Idioma: Inglés Año: 2020 Tipo del documento: Preprint
...